Merck KGaA suffers setback for cancer drug
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
Merck said in a statement it had decided to "voluntarily withdraw the marketing authorisation application to the European Medicines Agency" for Erbitux to be used to treat patients with advanced or metastatic non-small cell lung cancer.
The decision was "based on feedback from European regulatory authorities, indicating that further data would be required," the statement said.
It would not affect, however, "the proven utility of Erbitux in its already approved indications in metastatic colorectal cancer and head and neck cancer," Merck insisted.
"We are disappointed that we have not been able to move forward with the filing but it has become apparent that further data will be required to support the clinical utility of Erbitux in this specific population," said Merck's head of drug development, Annalisa Jenkins.
Already in July, Merck KGaA had said that phase III clinical trials of Erbitux for treatment of gastric cancer drug had shown no benefits of the drug for patients.
The news hit Merck KGaA shares which were showing a loss of 1.24 percent at 93.67 euros in mid-morning trade on the Frankfurt stock exchange in a generally softer market.
(c) 2012 AFP
-
Merck KGaA suffers setback on cancer drug
Jul 05, 2012 |
not rated yet |
0
-
Drug company Merck to cut 1 jobs in 10 in Germany
Sep 04, 2012 |
not rated yet |
0
-
Merck says US rejects its MS drug
Mar 02, 2011 |
not rated yet |
0
-
Clinical Data gets app nod for depression drug
May 24, 2010 |
not rated yet |
0
-
Facebook sidelines contested Merck profile page
Nov 29, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
19 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Small cancer risk following CT scans in childhood and adolescence confirmed
The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...
Cancer
8 hours ago |
not rated yet |
0
Changing cancer's environment to halt its spread
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
Cancer
9 hours ago |
not rated yet |
0
Novel RNA-based classification system for colorectal cancer
A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...
Cancer
9 hours ago |
not rated yet |
0
Low radiation scans help identify cancer in earliest stages
A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...
Cancer
11 hours ago |
not rated yet |
0
Poliovirus vaccine trial shows early promise for recurrent glioblastoma
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer
13 hours ago |
not rated yet |
0
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.
New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Reducing caloric intake delays nerve cell loss
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
Antidepressant reduces stress-induced heart condition
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.